China Resources Pharmaceutical Secures NAFMII Green Light for RMB5.00 Billion Medium-Term Note Programme

Bulletin Express05-29

China Resources Pharmaceutical Group Limited (commonly known as China Resources Pharmaceutical) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Co., Ltd., has received a Notice of Acceptance of Registration (Zhong Shi Xie Zhu [2026] No. MTN455) from the National Association of Financial Market Institutional Investors (NAFMII).

The registration permits the subsidiary to issue medium-term notes in mainland China with a combined principal amount of up to RMB5.00 billion over a two-year validity period. The notes may be launched in multiple tranches during this timeframe.

According to the filing, net proceeds from any issuance will be allocated primarily toward replenishing working capital, repaying interest-bearing debt and other uses permitted under applicable regulations.

The company stated it will release further information should the issuance proceed and advised shareholders and prospective investors to exercise caution when dealing in its securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185328539?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185328539","market":"hk","top_or_hot":-1,"title":"China Resources Pharmaceutical Secures NAFMII Green Light for RMB5.00 Billion Medium-Term Note Programme","media":"Bulletin Express","content":"<p>China Resources Pharmaceutical Group Limited (commonly known as China Resources Pharmaceutical) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Co., Ltd., has received a Notice of Acceptance of Registration (Zhong Shi Xie Zhu [2026] No. MTN455) from the National Association of Financial Market Institutional Investors (NAFMII).</p>\n<p>The registration permits the subsidiary to issue medium-term notes in mainland China with a combined principal amount of up to RMB5.00 billion over a two-year validity period. The notes may be launched in multiple tranches during this timeframe.</p>\n<p>According to the filing, net proceeds from any issuance will be allocated primarily toward replenishing working capital, repaying interest-bearing debt and other uses permitted under applicable regulations.</p>\n<p>The company stated it will release further information should the issuance proceed and advised shareholders and prospective investors to exercise caution when dealing in its securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Resources Pharmaceutical Secures NAFMII Green Light for RMB5.00 Billion Medium-Term Note Programme</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Resources Pharmaceutical Secures NAFMII Green Light for RMB5.00 Billion Medium-Term Note Programme\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-29 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Pharmaceutical Group Limited (commonly known as China Resources Pharmaceutical) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Co., Ltd., has received a Notice of Acceptance of Registration (Zhong Shi Xie Zhu [2026] No. MTN455) from the National Association of Financial Market Institutional Investors (NAFMII).</p>\n<p>The registration permits the subsidiary to issue medium-term notes in mainland China with a combined principal amount of up to RMB5.00 billion over a two-year validity period. The notes may be launched in multiple tranches during this timeframe.</p>\n<p>According to the filing, net proceeds from any issuance will be allocated primarily toward replenishing working capital, repaying interest-bearing debt and other uses permitted under applicable regulations.</p>\n<p>The company stated it will release further information should the issuance proceed and advised shareholders and prospective investors to exercise caution when dealing in its securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1185328539","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185328539","pubTimestamp":1780057401,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Pharmaceutical Group Limited (commonly known as China Resources Pharmaceutical) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Co., Ltd., has...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"华润医药50亿元中期票据计划获交易商协会批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharmaceutical Group Limited (commonly known as China Resources Pharmaceutical) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Co., Ltd., has received a Notice of Acceptance of Registration (Zhong Shi Xie Zhu [2026] No. MTN455) from the National Association of Financial Market Institutional Investors (NAFMII).\nThe registration permits the subsidiary to issue medium-term notes in mainland China with a combined principal amount of up to RMB5.00 billion over a two-year validity period. The notes may be launched in multiple tranches during this timeframe.\nAccording to the filing, net proceeds from any issuance will be allocated primarily toward replenishing working capital, repaying interest-bearing debt and other uses permitted under applicable regulations.\nThe company stated it will release further information should the issuance proceed and advised shareholders and prospective investors to exercise caution when dealing in its securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185328539","isCrawlerRequest":true}